Role of PCSK9 in the course of ejection fraction change after ST‐segment elevation myocardial infarction: a pilot study

AIMS: Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a therapeutic target for reducing plasma low‐density lipoprotein cholesterol. Beyond lipid control, recent findings suggest a deleterious effect of this protein in the pathogenesis of postmyocardial infarction left ventricle...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:ESC Heart Fail
Päätekijät: Miñana, Gema, Núñez, Julio, Bayés‐Genís, Antoni, Revuelta‐López, Elena, Ríos‐Navarro, César, Núñez, Eduardo, Chorro, Francisco J., López‐Lereu, Maria Pilar, Monmeneu, Jose Vicente, Lupón, Josep, Sanchis, Juan, Bodí, Vicent
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2020
Aiheet:
Original Research Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7083416/
https://ncbi.nlm.nih.gov/pubmed/31903686
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ehf2.12533
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia